{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:24:37Z","timestamp":1791919477040,"version":"4.3.4"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>The global burden of gout is rising, as are the prevalence of associated comorbidities, all-cause mortality and societal costs. In this review, we discuss recent advances in epidemiology and treatment strategies for gout.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Genetic factors and obesity are prominent contributors to hyperuricemia and gout, while dietary factors contribute to less variance in serum urate, though can still have some contribution to population attributable risk. A consensus statement by the Gout, Hyperuricemia and Crystal-Associated Disease Network outlined appropriate terminology regarding gout, which will aid in communication about various aspects of the disease. The 2020 American College of Rheumatology gout guideline offers comprehensive evidence-based recommendations for the management of hyperuricemia using urate-lowering therapy, prophylaxis when initiating urate-lowering therapy, treatment of gout flare and adjunctive management strategies. There is improved understanding of risk factors for allopurinol hypersensitivity syndrome and well tolerated use of allopurinol in chronic kidney disease. Trial data have provided new insights regarding cardiovascular risk with febuxostat. Several new drug therapies are being tested for both urate-lowering efficacy and gout flare management.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Although there have been significant advances in understanding of risk factors and treatment approaches, gout remains suboptimally managed. There is substantial need for improving gout management efforts and gout education among patients and clinicians.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000861","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T10:32:17Z","timestamp":1639564337000},"page":"118-124","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":89,"title":["Update on gout management: what is old and what is new"],"prefix":"10.1097","volume":"34","author":[{"given":"Yuliya","family":"Afinogenova","sequence":"first","affiliation":[{"name":"Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijeet","family":"Danve","sequence":"additional","affiliation":[{"name":"Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuhina","family":"Neogi","sequence":"additional","affiliation":[{"name":"Boston University School of Medicine, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,12,13]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1002\/art.41453","article-title":"Rising global burden of gout: time to act","volume":"72","author":"Danve","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/S0140-6736(18)32335-3","article-title":"Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories 1990\u20132017: a systematic analysis for the Global Burden of Disease Study","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/art.40807","article-title":"Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey","volume":"71","author":"Chen-Xu","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.semarthrit.2020.04.008","article-title":"Gout epidemiology and comorbidities","volume":"50","author":"Singh","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1002\/art.41008","article-title":"Cause-specific mortality in gout: novel findings of elevated risk of non-cardiovascular-related deaths","volume":"71","author":"Vargas-Santos","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/annrheumdis-2015-209058","article-title":"Improved survival in rheumatoid arthritis: a general population-based cohort study","volume":"76","author":"Zhang","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/annrheumdis-2016-210588","article-title":"The unclosing premature mortality gap in gout: a general population-based study","volume":"76","author":"Fisher","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.semarthrit.2015.02.004","article-title":"The economic burden of gout: a systematic review","volume":"45","author":"Rai","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.3899\/jrheum.151432","article-title":"Trends in emergency department visits and charges for gout in the United States between 2006 and","volume":"43","author":"Jinno","year":"2016","journal-title":"J Rheumatol"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1001\/jama.2016.3517","article-title":"Trends in gout and rheumatoid arthritis hospitalizations in the United States","volume":"315","author":"Lim","year":"2016","journal-title":"JAMA"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/acr.23607","article-title":"Gout, hyperuricemia, and crystal-associated disease network consensus statement regarding labels and definitions for disease elements in gout","volume":"71","author":"Bursill","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/art.41247","article-title":"2020 American College of Rheumatology Guideline for the Management of Gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/RHU.0000000000000235","article-title":"Does starting allopurinol prolong acute treated gout? A randomized clinical trial","volume":"21","author":"Hill","year":"2015","journal-title":"J Clin Rheumatol"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.amjmed.2012.05.025","article-title":"Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial","volume":"125","author":"Taylor","year":"2012","journal-title":"Am J Med"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jbspin.2015.02.021","article-title":"Significance of the initiation time of urate-lowering therapy in gout patients: a retrospective research","volume":"82","author":"Feng","year":"2015","journal-title":"Joint Bone Spine"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1002\/art.40233","article-title":"Effects of febuxostat in early gout: a randomized, double-blind, placebo-controlled study","volume":"69","author":"Dalbeth","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(18)32158-5","article-title":"Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial","volume":"392","author":"Doherty","year":"2018","journal-title":"Lancet"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"15","DOI":"10.7812\/TPP\/15-234","article-title":"Virtual gout management clinic for achieving target serum uric acid levels: a randomized clinical trial","volume":"20","author":"Goldfien","year":"2016","journal-title":"Perm J"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.amjmed.2018.11.011","article-title":"Adherence and outcomes with urate-lowering therapy: a site-randomized trial","volume":"132","author":"Mikuls","year":"2019","journal-title":"Am J Med"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/annrheumdis-2017-211574","article-title":"Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study","volume":"77","author":"Yamanaka","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/acr.24402","article-title":"Efficacy and safety of pharmacologic interventions in patients experiencing a gout flare: a systematic review and network meta-analysis","volume":"73","author":"Zeng","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"k3951","DOI":"10.1136\/bmj.k3951","article-title":"Evaluation of the diet wide contribution to serum urate levels: meta-analysis of population based cohorts","volume":"363","author":"Major","year":"2018","journal-title":"BMJ"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/art.41067","article-title":"Population impact attributable to modifiable risk factors for hyperuricemia","volume":"72","author":"Choi","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-019-0115-y","article-title":"Gout","volume":"5","author":"Dalbeth","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/art.30119","article-title":"Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment","volume":"63","author":"Stamp","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/art.34488","article-title":"Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol","volume":"64","author":"Stamp","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B\u22175801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"D784","DOI":"10.1093\/nar\/gku1166","article-title":"Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations","volume":"43","author":"Gonzalez-Galarza","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1053\/j.ajkd.2017.01.055","article-title":"Management of gout and hyperuricemia in CKD","volume":"70","author":"Vargas-Santos","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/art.39654","article-title":"Impact of febuxostat on renal function in gout patients with moderate-to-severe renal impairment","volume":"68","author":"Saag","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41584-021-00657-4","article-title":"Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities","volume":"17","author":"Stamp","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1056\/NEJMoa1915833","article-title":"Effects of allopurinol on the progression of chronic kidney disease","volume":"382","author":"Badve","year":"2020","journal-title":"N Engl J Med"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1056\/NEJMoa1916624","article-title":"Serum urate lowering with allopurinol and kidney function in Type 1 diabetes","volume":"382","author":"Doria","year":"2020","journal-title":"N Engl J Med"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/art.40583","article-title":"New perspectives in rheumatology: implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities trial and the associated Food and Drug Administration Public Safety Alert","volume":"70","author":"Choi","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","article-title":"Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, noninferiority trial","volume":"396","author":"Mackenzie","year":"2020","journal-title":"Lancet"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/art.41638","article-title":"Reassessing the cardiovascular safety of febuxostat: implications of the febuxostat versus allopurinol streamlined trial","volume":"73","author":"Choi","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40744-019-0151-9","article-title":"Use of pre-infusion serum uric acid levels as a biomarker for infusion reaction risk in patients on pegloticase","volume":"6","author":"Keenan","year":"2019","journal-title":"Rheumatol Ther"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3899\/jrheum.200460","article-title":"Pegloticase in combination with methotrexate in patients with uncontrolled gout: a multicenter, open-label study (MIRROR)","volume":"48","author":"Botson","year":"2021","journal-title":"J Rheumatol"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/art.41731","article-title":"Reducing immunogenicity of pegloticase with concomitant use of mycophenolate mofetil in patients with refractory gout: a phase II, randomized, double-blind, placebo-controlled trial","volume":"73","author":"Khanna","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.41550","article-title":"Trends in utilization of urate-lowering therapies following the US Food and Drug Administration's boxed warning on febuxostat","volume":"73","author":"Kim","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/acr2.11121","article-title":"Management of gout in the United States: a claims-based analysis","volume":"2","author":"Edwards","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.semarthrit.2017.09.007","article-title":"Medication adherence among patients with gout: a systematic review and meta-analysis","volume":"47","author":"Scheepers","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1093\/rheumatology\/kex250","article-title":"The British Society for Rheumatology Guideline for the Management of Gout","volume":"56","author":"Hui","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7326\/M16-0570","article-title":"Clinical Guidelines Committee of the American College of P, Denberg TD, Barry MJ, et al. Management of Acute and Recurrent Gout: a clinical practice guideline from the American College of Physicians","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann Intern Med"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000861","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:17:23Z","timestamp":1748294243000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,13]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000861","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,13]]}}}